PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

FDA Law Blog: Drug Discovery

NOVEMBER 10, 2024

Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.

Clinical Development 69

Clinical Development Production Clinical Trials Treatment 69

BioPharma Drive: Drug Pricing

DECEMBER 22, 2023

The deal would hand Bristol Myers, which has newly made neuroscience a therapeutic focus, an experimental treatment for schizophrenia.

Drug Development 196

Drug Development Treatment Drugs 196

Drug Target Review

DECEMBER 20, 2024

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

PPD

MARCH 11, 2025

Developing treatments for individuals living with rare diseases is critical, but orphan drug development is laden with unique obstacles that necessitate innovative, multifaceted approaches. Moreover, in some rare disease trials, it is unethical to design a control group of patients with a placebo.

Drug Development 52

Drug Development Clinical Trials Disease Trials 52

Quanticate

AUGUST 2, 2024

Real-world evidence (RWE) is changing clinical drug development, bridging the gap between controlled clinical trial environments and the complexities of everyday patient experiences.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

PPD

DECEMBER 16, 2024

Our annual look at the state of the drug development industry highlights a dual set of challenges complicating progress. Rising costs have become a persistent challenge for drug developers, driven by a combination of internal and external pressures that have intensified in recent years.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. But a new path for bringing treatments to patients is starting to emerge. We all recognize the vast, unmet medical need.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

Drug Target Review

APRIL 7, 2025

Susceptibility or risk biomarkers can detect the likelihood of a patient developing a disease or medical condition, which is crucial for treatments that are most effective before the onset of symptoms. A biomarker is a measurable indicator of a biological process, disease state, or response to a treatment.

Clinical Development 69

Clinical Development Clinical Trials Clinical Pharmacology Trials 69

Science Daily: Pharmacology News

AUGUST 9, 2023

The drug tecovirimat is currently in use for the treatment of mpox -- the disease caused by monkeypox virus -- that spread worldwide in 2022. Tecovirimat is an anti-poxviral drug, and its use is driving the emergence of drug-resistant variants of the monkeypox virus.

Licensing 146

Licensing Licensing Treatment Virus 146

PPD

SEPTEMBER 25, 2023

As the clinical trial landscape evolves, drug developers are faced with novel challenges and changes in study recruitment, trial size and structure, and more. The adoption of new innovations, strategies and technologies offers opportunities to address persistent challenges and develop suitable approaches for the future.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

BioPharma Drive: Drug Pricing

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 146

Drug Development Drugs Therapies Treatment 146

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Target Review

DECEMBER 23, 2024

Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. Properly managing these toxicities is crucial to enhancing the safety and therapeutic effectiveness of ADC treatments.

Research 52

Research Treatment Therapies Drug Development 52

Drug Target Review

NOVEMBER 25, 2024

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

Drug Target Review

MARCH 17, 2025

Neuropsychiatric treatment is on the verge of a major transformation. Historically, treatment options have been limited, with patients relying on daily medications that have minimal efficacy and troublesome side effects. “Zelquistinel is a positive modulator of NMDA receptors,” Donello explains.

Treatment 52

Treatment Licensing Licensing Science 52

BioPharma Drive: Drug Pricing

JULY 10, 2023

Why dedicated expertise and a collaborative approach are needed to help smaller biotech companies bring new cancer treatments to light, now perhaps more than ever before

Drug Development 130

Drug Development Treatment Drugs 130

DrugBank

JUNE 6, 2024

In the rapidly evolving landscape of oncology drug development, artificial intelligence (AI) has emerged as a revolutionary force, altering not just the pace but the very methodology of discovery and development.   What sets RADR ® apart is its robust data-driven approach.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

Drug Patent Watch

OCTOBER 16, 2024

Biosimilars, which are biologic drugs that are highly similar to an already approved biologic drug, are transforming the pharmaceutical industry. As patents for original biologic drugs expire, biosimilars are becoming increasingly important, offering more affordable treatment options for patients and healthcare systems.

Biosimilars 115

Biosimilars Drug Development Drugs Pharmaceuticals 115

keypoint

APRIL 22, 2025

As such, we have a long history of partnership with industry leaders with the shared goal of integrating basic science discovery and innovation into drug development efforts to yield novel and improved targeted treatment strategies.

Drug Development 82

Drug Development Science Treatment Drugs 82

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs 96

Drugs Drug Development Pharmaceuticals Production 96

Quanticate

SEPTEMBER 13, 2024

With the implementation of technology rapidly increasing, stricter regulatory standards, and growing demand for innovative treatments, the trends within the industry continue to evolve, impacting the future of clinical trials both positively and negatively.

Clinical Trials 95

Clinical Trials Trials Drug Development Treatment 95

Chemical Biology and Drug Design

MAY 11, 2023

The results suggest that scFv-ACLP fusion proteins may be potential anticancer drug candidates for targeted cancer treatment. Abstract Antibody-directed drugs for targeted cancer treatment have become a hot topic in new anticancer drug development; however, antibody-fused therapeutic peptides were rarely documented.

Treatment 100

Treatment Drug Development Drugs Research 100

Chemical Biology and Drug Design

OCTOBER 20, 2023

Enzymes involved in glucose metabolism may be promising therapeutic targets for drug development against the pathogenic free-living amoebae. Unfortunately, the efficacy of these can be limited, driving the need for the discovery of new treatments.

Treatment 100

Treatment Small Molecule Drug Development Drugs 100

Drug Target Review

OCTOBER 30, 2024

Organoids have been developed for the pancreas, stomach, colon, liver, kidney, thyroid, and heart, among others. 9,10 To reach this goal, the next generation of organoid development approaches use combinations of different cell types together in a 3D culture to form a more complex organoid that better mimics the complexity of tissues.

Treatment 105

Treatment Disease Clinical Trials Research 105

Alta Sciences

APRIL 17, 2024

Five Promising Treatment Areas in Early-Phase Drug Development in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drug development is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Conversations in Drug Development Trends

AUGUST 14, 2024

By: Simran Padam, Medical Director, Medical Affairs Personalized treatment approaches have emerged as pivotal in improving outcomes for hematological cancers. Hematological cancer cells can also develop resistance to therapies over time, reducing treatment effectiveness.

Treatment 78

Treatment Therapies Disease Protein Expression 78

PLOS: DNA Science

MARCH 28, 2024

A new drug has entered the arsenal against Duchenne muscular dystrophy (DMD), a genetic disease that affects boys and is challenging to treat. FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. In 2023, two gene-based treatments became available.

FDA Approval 96

FDA Approval Treatment FDA DNA 96

Drug Target Review

AUGUST 7, 2024

The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drug development process, particularly as the field is highly regulated by health authorities around the world.

Drug Development 59

Drug Development Clinical Pharmacology Clinical Trials Drugs 59

Conversations in Drug Development Trends

NOVEMBER 21, 2023

Since the advent of modern medicine, the scientific community has developed more than 3,000 drugs for thousands of diseases. Despite significant progress, there are more than 6,500 rare diseases without a single approved treatment. There are so many patients suffering from diseases that have no treatments.

Disease 78

Disease Treatment Clinical Trials Clinical Development 78

LifeSciVC

FEBRUARY 27, 2024

By Ivana Magovčević-Liebisch, CEO of Vigil Neuroscience, as part of the From The Trenches feature of LifeSciVC Patients and their care partners are at the center of our work in the life sciences industry – but at what point during the drug development process should companies start to engage these key stakeholders?

Drug Development 69

Drug Development Disease Drugs Treatment 69

Conversations in Drug Development Trends

JANUARY 21, 2025

Bioanalysis during clinical development of a drug is an indispensable process where trials obtain critical data pertinent to pharmacokinetics (PK) and pharmacodynamics (PD) and as readouts that are crucial for assessing the safety and efficacy of the drugs.

Clinical Trials 78

Clinical Trials Laboratories Trials Drug Development 78

Quanticate

JULY 5, 2024

It’s essential for maintaining ethical standards, high-quality outcomes and facilitating global standardisation, enabling multi-center and multinational studies, thereby streamlining the development and approval process for new medical treatments, and maintaining public trust in clinical research.

Clinical Research 111

Clinical Research Drug Development Treatment Research 111

Crown Bioscience

MARCH 14, 2025

The Importance of Biomarkers in Drug Development Biomarkers have become essential tools in modern drug discovery and development, enabling researchers to predict drug efficacy, monitor disease progression, and tailor treatments to specific patient populations.

Drug Development 52

Drug Development Clinical Trials Drugs Drug Research 52

Drug Discovery Today

AUGUST 16, 2021

Monument recently raised £2.625 million in seed funding and applies a novel drug development strategy, leveraging digital assessments of cognition to match patients with new pharmaceutical treatments.

Drug Development 113

Drug Development Pharmaceuticals Treatment Drugs 113

Alta Sciences

AUGUST 29, 2024

Engaging at the outset with a fully integrated and experienced drug development partner can ensure safety, with timely data sharing at every step of the drug development plan, and facilitate agile, flexible decision-making and planning. billion USD in 2023 to $166.53 billion USD by 2028.

Drug Development 52

Drug Development Clinical Trials Small Molecule Drugs 52